Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neoplasms

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,337 result(s) found for: Neoplasms. Displaying page 1 of 267.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-005967-33 Sponsor Protocol Number: lung1 Start Date*: 2009-02-20
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESI
    Full Title: randomized phase II trial of two different sequences in first line chemotherapy of advanced non small cell lung cancer
    Medical condition: non small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062042 PT
    9.1 10029104 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000269-30 Sponsor Protocol Number: MO29518 Start Date*: 2015-08-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL, MULTICOHORT, PHASE II STUDY OF ATEZOLIZUMAB IN ADVANCED SOLID TUMORS
    Medical condition: Patients with histologically documented advanced solid tumors that meet protocol-defined cohort specifications, have progressed following at least one line of prior systemic anticancer therapy, or ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062042 Lung neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072737 Advanced breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039491 Sarcoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071114 Metastatic gastric adenocarcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043670 Thymoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008593 Cholangiocarcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041823 Squamous cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004655 Biliary carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061184 Germ cell cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008229 Cervical cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061306 Nasopharyngeal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027412 Mesotheliomas HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) IE (Completed) AT (Completed) ES (Completed) FI (Completed) GB (Completed) DK (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000851-15 Sponsor Protocol Number: M19CVT Start Date*: 2020-01-16
    Sponsor Name:NKI-AVL
    Full Title: Treatment of metastatic vulvar carcinoma in a neoadjuvant setting with Carboplatin and Paclitaxel chemotherapy
    Medical condition: vulvar carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047750 Vulval neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004078-89 Sponsor Protocol Number: 0001741 Start Date*: Information not available in EudraCT
    Sponsor Name:DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO
    Full Title: RINSING WITH DESAMETASONE VERSUS RINSING WITH BENZIDAMINE IN THE PREVENTION OF MUCOSITES CORRELATED TO CHEMIORADIOTHERAPY IN PATIENTS WITH CANCERS OF THE CERVIC-FACIAL DISTRICT-Studio DEXWASH
    Medical condition: patients with cervico-facial neoplasms receiving concomitant chemoradiotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004749-41 Sponsor Protocol Number: NEO-ONE Start Date*: 2011-12-13
    Sponsor Name:TweeSteden hospital
    Full Title: The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate-risk prostate carcinoma (NEO-ONE); A randomized controlled trial
    Medical condition: Localized prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019756-42 Sponsor Protocol Number: ECF-DCF Start Date*: 2011-03-01
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: Sequential first line chemotherapy ECF (epirubicin + cisplatin + 5-fluoruracil) followed by DCF (docetaxel + cisplatin + 5-fluoruracil) in advanced/metastatic gastric cancer HER-2 negative: a phase...
    Medical condition: patients with advanced/metastatic gastric cancer not operable HER-2 negative
    Disease: Version SOC Term Classification Code Term Level
    13.1 10017947 - Gastrointestinal disorders 10017812 Gastric neoplasms malignant HLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017991 Gastrointestinal neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005751-21 Sponsor Protocol Number: BLU-285-1408 Start Date*: 2021-04-16
    Sponsor Name:Blueprint Medicines
    Full Title: Open-Label Extension Study to Evaluate the Safety of Long-Term Treatment with Avapritinib for Patients Previously Involved in an Avapritinib Study
    Medical condition: Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051066 Gastrointestinal stromal tumour PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003102-14 Sponsor Protocol Number: IFG-NIB-01 Start Date*: 2017-09-19
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: A PHASE II ONE-ARM OPEN-LABEL NEOADJUVANT STUDY OF PEMBROLIZUMAB IN COMBINATION WITH NAB-PACLITAXEL FOLLOWED BY PEMBROLIZUMAB IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH TR...
    Medical condition: Female patients with early, neoadjuvantly treated, triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021976 Inflammatory breast cancer stage IV LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071115 Node-negative breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071113 Node-positive breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021974 Inflammatory breast cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021975 Inflammatory breast cancer stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063103 Tubular breast cancer stage I LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006194 Breast cancer NOS stage I LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063104 Tubular breast cancer stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006196 Breast cancer NOS stage III LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063102 Tubular breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006195 Breast cancer NOS stage II LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006190 Breast cancer invasive NOS LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006192 Breast cancer NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063105 Tubular breast cancer stage III LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006199 Breast cancer stage I PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006200 Breast cancer stage II PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054784 Contralateral breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10021944 Infiltrating ductal breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073289 Premenopausal breast cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10022882 Invasive ductal breast cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006283 Breast neoplasm malignant female LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003820-37 Sponsor Protocol Number: IGIT-008 Start Date*: 2005-02-10
    Sponsor Name:Bracco Imaging Spa
    Full Title: A multicentre study to evaluate the Contibution of SonoVue® and CnTI technology (Contrast Tuned Imaging) to a correct classification of Adnexal Masses as benign or malignant
    Medical condition: COMPLEX ADNEXAL MASS IN PELVIS
    Disease: Version SOC Term Classification Code Term Level
    10029104 SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000466-33 Sponsor Protocol Number: PT/11/2015 Start Date*: 2016-03-22
    Sponsor Name:Department of Pediatric oncology, Aarhus University hospital
    Full Title: Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia.
    Medical condition: Pediatric oncology patients with fever and neutropenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10007050 Cancer LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000513-36 Sponsor Protocol Number: VIRN2012 Start Date*: 2012-06-18
    Sponsor Name:A.U.S.L. RIMINI
    Full Title: Validation of the use of lymphography with green indocyanine in identifying the sentinel node in breast cancer
    Medical condition: WOMAN BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024298-37 Sponsor Protocol Number: ESOT/1/2010 Start Date*: 2011-03-28
    Sponsor Name:Dipartimento Integrato di Oncologia, Ematologia e Patologie dell'Apparato Respiratorio
    Full Title: Early strong opiod treatment in cancer pain -Morphine vs weak opiods
    Medical condition: Tumor Pain, mild-moderate intensity (VAS 3-7)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-004126-17 Sponsor Protocol Number: GOIM22001 Start Date*: 2013-03-04
    Sponsor Name:GOIM GRUPPO ONCOLOGICO MERIDIONALE
    Full Title: Cisplatin and capecitabine (ECX) in stomach adenocarcinoma()tratment in advanced stage.Multicenter randomized phase II trial foolwed by GOIM.
    Medical condition: Gastric Cancer HER2 negative
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007241-12 Sponsor Protocol Number: PH-L19SIPI131-07/07 Start Date*: 2008-10-06
    Sponsor Name:Philogen S.p.A.
    Full Title: A PHASE I/II DOSE FINDING AND EFFICACY STUDY OF THE TUMOUR TARGETING HUMAN 131I-L19SIP MONOCLONAL ANTIBODY IN PATIENTS WITH CANCER
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006796-80 Sponsor Protocol Number: TES10897 Start Date*: 2009-04-23
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: The QUTIE Study: A Randomized, Double-Blind, Placebo-controlled Study Comparing Aflibercept Versus Placebo on the QTc interval in Cancer Patients treated with Docetaxel
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    11.0 10007050 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002046-20 Sponsor Protocol Number: IOVHN12012 Start Date*: 2012-05-28
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO
    Full Title: Role of SAMITAL in prevention and treatment of oral mucositis in patients treated with chemo-radiation (CT/RT)for head-and-neck squamous cell carcinomas. A double-blind, Phase 2 placebo controlled,...
    Medical condition: Head-and-neck cancer (Squamous cell carcinomas)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002036-24 Sponsor Protocol Number: Uni-koeln-1612 Start Date*: 2014-06-24
    Sponsor Name:University of Cologne
    Full Title: A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer
    Medical condition: Patients with BRCA1- or BRCA2-associated advanced breast- and ovarian cancer which are refractory to standard therapy and for which no suitable, effective/curative therapy exists.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000699-40 Sponsor Protocol Number: BR55-102 Start Date*: 2012-07-26
    Sponsor Name:BRACCO IMAGING
    Full Title: A Study of BR55 in Contrast Enhanced Ultrasound Imaging in Patients with Ovarian and Breast Cancer.
    Medical condition: Patients with ovarian or breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001739-21 Sponsor Protocol Number: FiDoAp Start Date*: 2012-03-26
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: A study of Sativex for pain Relief and appetite stimulation in Patients with advanced malignancy. Phase II
    Medical condition: advanced malignant cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000869-21 Sponsor Protocol Number: Ima-NF1-2012 Start Date*: 2012-04-12
    Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA"
    Full Title: Pilot study: Imatinib for the treatment of plexiform neurofibromas in NF1 patients.
    Medical condition: Patients with NF1 and plessiform neurofibromas
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 11:32:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA